Protalix BioTherapeutics, Inc. (PLX) vs Pyxis Oncology, Inc. (PYXS)
- Protalix BioTherapeutics, Inc. PLX 2.62 −2.96%
- Pyxis Oncology, Inc. PYXS 1.67 −7.22%
Protalix BioTherapeutics, Inc. and Pyxis Oncology, Inc. are both Biotechnology companies. Protalix BioTherapeutics, Inc. and Pyxis Oncology, Inc. are of similar size ($217.5M and $215.3M). Pyxis Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.4×. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs 0.00%). Across the 13 metrics below, Protalix BioTherapeutics, Inc. leads on 11 and Pyxis Oncology, Inc. on 2.
Valuation
Profitability
| Metric | PLX | PYXS | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.20% | 0.00% | 65.16% |
| Operating margin | 28.89% | 0.00% | 0.00% |
| Net margin | 23.50% | 0.00% | 0.00% |
| Free cash flow margin | 9.51% | 0.00% | 0.00% |
| Return on equity | 31.23% | (179.10%) | (56.36%) |
| Return on assets | 20.07% | (99.62%) | (48.04%) |
| Return on invested capital | 48.48% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack